ES2530694T3 - Factor de permisividad celular para virus, y usos del mismo - Google Patents

Factor de permisividad celular para virus, y usos del mismo Download PDF

Info

Publication number
ES2530694T3
ES2530694T3 ES05736317T ES05736317T ES2530694T3 ES 2530694 T3 ES2530694 T3 ES 2530694T3 ES 05736317 T ES05736317 T ES 05736317T ES 05736317 T ES05736317 T ES 05736317T ES 2530694 T3 ES2530694 T3 ES 2530694T3
Authority
ES
Spain
Prior art keywords
viruses
factor
permissiveness
cellular
increased expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05736317T
Other languages
English (en)
Inventor
Jay Calvert
Shelly Shields
David Slade
Siao-Kun Welch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis P&U LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis P&U LLC filed Critical Zoetis P&U LLC
Application granted granted Critical
Publication of ES2530694T3 publication Critical patent/ES2530694T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0688—Cells from the lungs or the respiratory tract
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un procedimiento in vitro para facilitar la infección de una célula de vertebrado por el VSRRP que comprende las etapas de (a) dirigir la expresión aumentada de un polipéptido de CD163 por dicha célula de vertebrado en la que dicho polipéptido de CD163 comprende un dominio transmembrana, y en la que dicha expresión aumentada se logra mediante la introducción de ácido nucleico exógeno.
ES05736317T 2004-04-23 2005-04-05 Factor de permisividad celular para virus, y usos del mismo Expired - Lifetime ES2530694T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56521404P 2004-04-23 2004-04-23
US63473604P 2004-12-09 2004-12-09
PCT/US2005/011502 WO2005107796A2 (en) 2004-04-23 2005-04-05 Cellular permissivity factor for viruses, and uses thereof

Publications (1)

Publication Number Publication Date
ES2530694T3 true ES2530694T3 (es) 2015-03-04

Family

ID=35320736

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12178283T Expired - Lifetime ES2570665T3 (es) 2004-04-23 2005-04-05 Factor de permisividad celular para virus, y usos del mismo
ES05736317T Expired - Lifetime ES2530694T3 (es) 2004-04-23 2005-04-05 Factor de permisividad celular para virus, y usos del mismo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES12178283T Expired - Lifetime ES2570665T3 (es) 2004-04-23 2005-04-05 Factor de permisividad celular para virus, y usos del mismo

Country Status (21)

Country Link
US (4) US7754464B2 (es)
EP (2) EP1742658B1 (es)
JP (2) JP5273642B2 (es)
CN (1) CN102220289B (es)
AR (3) AR049033A1 (es)
AU (2) AU2005240002B2 (es)
BR (1) BRPI0508928B1 (es)
CA (1) CA2564769C (es)
CL (1) CL2008002323A1 (es)
DK (1) DK1742658T3 (es)
EA (1) EA013071B1 (es)
ES (2) ES2570665T3 (es)
IL (1) IL178160A0 (es)
MA (1) MA28544B1 (es)
MX (1) MXPA06012216A (es)
NO (1) NO341211B1 (es)
NZ (1) NZ550145A (es)
PL (1) PL1742658T3 (es)
TW (2) TWI438278B (es)
UY (1) UY28867A1 (es)
WO (1) WO2005107796A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013071B1 (ru) * 2004-04-23 2010-02-26 ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи Способ получения вируса репродуктивно-респираторного синдрома свиней (pprsv) и способ получения pprsv вакцины
MX2009007457A (es) * 2007-01-12 2009-08-12 Univ Illinois Celulas que no son de mono para el desarrollo del virus del sindrome porcino reproductor y respiratorio (prrs).
ES2567561T3 (es) * 2007-07-27 2016-04-25 Universiteit Gent Células permisivas y sus usos
UA108902C2 (uk) * 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
KR102012109B1 (ko) * 2012-05-17 2019-08-19 조에티스 엘엘씨 이유 전 돼지 생식기 호흡기 증후군(prrs) 바이러스에 대한 효과적인 백신접종
CN103525766B (zh) * 2013-03-24 2015-06-17 西北农林科技大学 一种猪肾细胞系及其应用
GB201313235D0 (en) 2013-07-24 2013-09-04 Univ Edinburgh Antiviral Compositions Methods and Animals
CN104459160A (zh) * 2014-12-30 2015-03-25 洛阳普莱柯万泰生物技术有限公司 试剂盒及其制备方法和使用方法
GB201617559D0 (en) 2016-10-17 2016-11-30 University Court Of The University Of Edinburgh The Swine comprising modified cd163 and associated methods
CA3047294A1 (en) * 2016-12-14 2018-06-21 Zoetis Services Llc Effective vaccination against european strains of porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
CN108103099B (zh) * 2017-12-18 2022-03-04 中山大学 一种抗蓝耳病Marc-145细胞系及其制备方法和应用
CN108893450B (zh) * 2018-08-13 2022-04-19 江苏省农业科学院 先天性免疫系统重构的bhk21细胞群及其细胞克隆增毒应用
CN111996213A (zh) * 2020-02-06 2020-11-27 广西大学 猪繁殖与呼吸综合征病毒双荧光标记基因重组毒株的构建方法
KR102254246B1 (ko) * 2020-03-23 2021-05-20 큐벳 주식회사 항-cd163 항체 또는 이의 항원 결합 단편을 인코딩하는 핵산 분자 및 이를 포함하는 아데노바이러스 벡터, 및 이의 아프리카 돼지열병의 예방 또는 치료용도
US11796548B2 (en) * 2020-04-22 2023-10-24 The United States Of America, As Represented By The Secretary Of Agriculture Continuous stable cell line for identification of infectious African swine fever virus in clinical samples
CN120302994A (zh) 2022-12-06 2025-07-11 硕腾服务有限责任公司 用于针对prrs-1病毒对仔猪进行疫苗接种的方法和组合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
CA1303983C (en) 1987-03-27 1992-06-23 Robert W. Rosenstein Solid phase assay
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
GB2236186B (en) 1989-08-22 1994-01-05 Finnigan Mat Gmbh Process and device for laser desorption of analyte molecular ions, especially of biomolecules
HU217212B (hu) 1989-12-22 1999-12-28 Applied Research Systems, ARS Holding M.V. Endogén gének expressziójának módosítása szabályozóelemmel
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
AU664847B2 (en) 1991-05-15 1995-12-07 Cell Genesys, Inc. Genomic modifications with homologous DNA targeting
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
US5514545A (en) 1992-06-11 1996-05-07 Trustees Of The University Of Pennsylvania Method for characterizing single cells based on RNA amplification for diagnostics and therapeutics
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
WO1994028418A1 (en) 1993-05-28 1994-12-08 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
ES2165405T3 (es) * 1994-04-11 2002-03-16 Akzo Nobel Nv Cepas de vacuna europeas del virus del sindrome reproductor y respiratorio porcino (prrsv).
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
WO1998035023A1 (en) * 1997-02-07 1998-08-13 Origen, Inc. Method for growing porcine reproductive and respiratory syndrome virus for use as vaccines and diagnostic assays
US6740490B2 (en) 2001-01-29 2004-05-25 Kansas State University Research Foundation Identification and applications of porcine reproductive and respiratory syndrome virus host susceptibility factor(s) for improved swine breeding
EP1414984B1 (en) 2001-07-24 2018-07-04 Universiteit Gent Nucleic acid encoding polypeptide involved in cellular entrance of the prrs virus
WO2003100419A1 (en) * 2002-05-27 2003-12-04 Bioceros B.V. Methods for using the cd163 pathway for modulating an immune response
EA013071B1 (ru) * 2004-04-23 2010-02-26 ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи Способ получения вируса репродуктивно-респираторного синдрома свиней (pprsv) и способ получения pprsv вакцины

Also Published As

Publication number Publication date
EP1742658A2 (en) 2007-01-17
HK1109065A1 (en) 2008-05-30
JP5273642B2 (ja) 2013-08-28
CN102220289B (zh) 2014-05-21
EP1742658B1 (en) 2014-12-24
AR084529A2 (es) 2013-05-22
EA200601677A1 (ru) 2007-10-26
BRPI0508928B1 (pt) 2015-10-06
JP2007533321A (ja) 2007-11-22
EP1742658A4 (en) 2007-11-28
MXPA06012216A (es) 2007-01-17
AR049033A1 (es) 2006-06-21
CA2564769A1 (en) 2005-11-17
US20120015425A1 (en) 2012-01-19
AU2009202410A1 (en) 2009-07-09
CL2008002323A1 (es) 2008-12-19
DK1742658T3 (en) 2015-01-19
PL1742658T3 (pl) 2015-05-29
TW200604343A (en) 2006-02-01
IL178160A0 (en) 2006-12-31
UY28867A1 (es) 2005-11-30
NO20065115L (no) 2006-11-06
US20140141492A1 (en) 2014-05-22
JP2013078324A (ja) 2013-05-02
US8486685B2 (en) 2013-07-16
US8058050B2 (en) 2011-11-15
BRPI0508928A (pt) 2007-08-14
JP5600340B2 (ja) 2014-10-01
AU2005240002B2 (en) 2009-06-18
US9102912B2 (en) 2015-08-11
TWI438278B (zh) 2014-05-21
NZ550145A (en) 2009-07-31
US20050271685A1 (en) 2005-12-08
US7754464B2 (en) 2010-07-13
TWI354025B (en) 2011-12-11
US20100273238A1 (en) 2010-10-28
EP2520310B1 (en) 2016-03-30
AU2005240002A1 (en) 2005-11-17
MA28544B1 (fr) 2007-04-03
CN102220289A (zh) 2011-10-19
EA013071B1 (ru) 2010-02-26
WO2005107796A3 (en) 2007-04-12
TW201134944A (en) 2011-10-16
EP2520310A1 (en) 2012-11-07
WO2005107796A2 (en) 2005-11-17
NO341211B1 (no) 2017-09-11
AR084530A2 (es) 2013-05-22
CA2564769C (en) 2013-12-17
ES2570665T3 (es) 2016-05-19

Similar Documents

Publication Publication Date Title
ES2570665T3 (es) Factor de permisividad celular para virus, y usos del mismo
CR9897A (es) Metodo de produccion proteica utilizando carnosina
ES2525518T3 (es) Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
CL2008003794A1 (es) Virus de la estomatitis vesicular geneticamente modificado (vsv) que comprende por lo menos una mutacion de aminoacido en una region de alguna de las proteinas m, g y l del virus; metodo para producirlo; composicion inmunogenica que lo comprende; metodo para adaptar un virus en un cultivo celular.
BRPI0516221A (pt) método de produção de vìrus de uma cultura de células, composição, e, método de produção de reovìrus infeccioso
AR111785A2 (es) Método in vitro de producción de eritrocitos
PE20091218A1 (es) Anticuerpo anti-glipicano 3 con cinetica en plasma mejorada
EA201101141A1 (ru) Получение закрытой линейной днк
UY35020A (es) Desempeño de ubicación de fad2 y su correspondiente sitio de incidencia específica de las proteínas de unión capaces de inducir rupturas ya seleccionadas.
AR086932A2 (es) Metodo para la produccion de polipeptidos
DK1939281T4 (da) Immortaliserede andecellelinjer til virusproduktion
DK1427817T3 (da) Formering af vira i cellekultur
AR088824A2 (es) Metodo para la produccion de tnfr-ig (receptor de factor de necrosis tumoral-inmunoglobulina)
PE20090731A1 (es) Metodos de produccion de proteinas basados en medios de cultivos celulares que comprenden compuestos anti-senescencia
CL2011002082A1 (es) Composicion farmaceutica que comprende un inhibidor de nucleosido polimerasa y un inhibidor de proteasa macrociclica; proceso para preparar dicha composicion farmaceutica; metodo para tratar o mejorar una infeccion con virus de la hepatitis c, fibrosis hepatica y alteracion de la funcion hepatica.
AR039465A1 (es) Sistema multi plasmid para la produccion de virus influenza
MX2016009805A (es) Proteinas inmovilizadas y uso de las mismas.
BRPI0711332A2 (pt) processo para otimização da distribuição de carga entre uma primeira rede de rádio móvel e uma segunda rede de rádio móvel
CL2020002450A1 (es) Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular
MX2018006373A (es) Produccion de virus en cultivos celulares.
ATE544848T1 (de) Cokultur-lte (lymphoid tissue equivalent) für artifizielles immunsystem (ais)
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
CY1111253T1 (el) Μεθοδος για την παραγωγη ιικου υλικου
DK1688146T3 (da) Fremstilling af aldesleukin til farmaceutisk anvendelse
ES2479543T1 (es) Poblaciones celulares que tienen actividad inmunorreguladora, métodos para la preparación y usos de las mismas